2. Association between mammographic features and Her2-positive breast cancer
Main Article Content
Abstract
The objective of this study was to determine the association between mammographic imaging features and HER2-positive breast cancer. A cross-sectional descriptive study was conducted on 553 patients with invasive ductal carcinoma at K Hospital from March 2022 to October 2023. Mammographic features were analyzed and compared with postoperative molecular subtypes of breast cancer, classified according to the 2015 St. Gallen Consensus. The results showed that the prevalence of HER2-positive breast cancer was 29.1%. Univariate and multivariate logistic regression analyses revealed that the presence of calcifications, density asymmetry, and nipple retraction significantly increased the likelihood of HER2 positivity, with odds ratios (OR) of 13.492, 14.859, and 1.632, respectively (p < 0.05). Conversely, mass lesions with spiculated margins were associated with a decreased likelihood of HER2 positivity (OR = 0.483, p < 0.05).
Article Details
Keywords
Mammography, breast cancer, HER2-positive
References
1. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. Nov 1 2013; 31(31): 3997-4013. doi:10.1200/jco.2013.50.9984.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY). Jan 9 1987; 235(4785): 177-82. doi:10.1126/science.3798106.
3. Loibl S, Gianni L. HER2-positive breast cancer. The Lancet. 2017; 389(10087): 2415-2429. doi:10.1016/S0140-6736(16)32417-5.
4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine. Feb 19 2015; 372(8): 724-34. doi:10.1056/NEJMoa1413513.
5. Portnow LH, Kochkodan-Self JM, Maduram A, et al. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics: a review publication of the Radiological Society of North America, Inc. Feb 2023; 43(2): e220103. doi:10.1148/rg.220103.
6. Song SE, Bae MS, Chang JM, Cho N, Ryu HS, Moon WK. MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiol. 2017 Jul; 58(7): 792-799. doi: 10.1177/0284185116673119. Epub 2016 Oct 17. PMID: 27754920.
7. Elias SG, Adams A, Wisner DJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2014; 23(8): 1464-83. doi:10.1158/1055-9965.Epi-13-1170.
8. Fowler EE, Sellers TA, Lu B, Heine JJ. Breast Imaging Reporting and Data System (BI-RADS) breast composition descriptors: automated measurement development for full field digital mammography. Medical physics. Nov 2013; 40(11): 113502. doi:10.1118/1.4824319.
9. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). Jul 2015; 10(3): 211-9. doi:10.1159/000433590.
10. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22; 321(3): 288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505.
11. Institute NC. Cancer stat facts: female breast cancer. National Cancer Institute Bethesda, MA; 2020.
12. Hoang TH, Phung Thi HT. 15P HER2-positive breast cancer in a low-middle income country (LMIC): Lack of pathology capability and the urgent need for targeted treatment. Annals of Oncology. 2024; 35: S1410. doi:10.1016/j.annonc.2024.10.035.
13. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. Jan 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.
14. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. Aug 2012; 23 Suppl 6:vi23-9. doi:10.1093/annonc/mds191.
15. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging. 2020; 3(1): 12-24. doi:10.1093/jbi/wbaa110 %J Journal of Breast Imaging.
16. Ramírez-Galván, Yazmín & Uribe-Martinez, Minerva & Ponce-Camacho, Marco & Montemayor, Alberto. (2022). Spiculated margin on ultrasound is associated with tumor grade and immunohistochemical profile in breast cancer. Journal of the Mexican Federation of Radiology and Imaging. 1. 10.24875/JMEXFRI.M22000016.
17. Mansour S, Abdullah E, Mohamed EH, Gomaa MMM. Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation. Egyptian Journal of Radiology and Nuclear Medicine. 2023/07/14 2023; 54(1): 122. doi:10.1186/s43055-023-01063-4.
18. Liu G, Li Y, Chen SL, Chen Q. Non-mass enhancement breast lesions: MRI findings and associations with malignancy. Annals of translational medicine. Mar 2022; 10(6): 357. doi:10.21037/atm-22-503.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, NY). Jan 9 1987; 235(4785): 177-82. doi:10.1126/science.3798106.
3. Loibl S, Gianni L. HER2-positive breast cancer. The Lancet. 2017; 389(10087): 2415-2429. doi:10.1016/S0140-6736(16)32417-5.
4. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine. Feb 19 2015; 372(8): 724-34. doi:10.1056/NEJMoa1413513.
5. Portnow LH, Kochkodan-Self JM, Maduram A, et al. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics: a review publication of the Radiological Society of North America, Inc. Feb 2023; 43(2): e220103. doi:10.1148/rg.220103.
6. Song SE, Bae MS, Chang JM, Cho N, Ryu HS, Moon WK. MR and mammographic imaging features of HER2-positive breast cancers according to hormone receptor status: a retrospective comparative study. Acta Radiol. 2017 Jul; 58(7): 792-799. doi: 10.1177/0284185116673119. Epub 2016 Oct 17. PMID: 27754920.
7. Elias SG, Adams A, Wisner DJ, et al. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Aug 2014; 23(8): 1464-83. doi:10.1158/1055-9965.Epi-13-1170.
8. Fowler EE, Sellers TA, Lu B, Heine JJ. Breast Imaging Reporting and Data System (BI-RADS) breast composition descriptors: automated measurement development for full field digital mammography. Medical physics. Nov 2013; 40(11): 113502. doi:10.1118/1.4824319.
9. Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). Jul 2015; 10(3): 211-9. doi:10.1159/000433590.
10. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan 22; 321(3): 288-300. doi: 10.1001/jama.2018.19323. PMID: 30667505.
11. Institute NC. Cancer stat facts: female breast cancer. National Cancer Institute Bethesda, MA; 2020.
12. Hoang TH, Phung Thi HT. 15P HER2-positive breast cancer in a low-middle income country (LMIC): Lack of pathology capability and the urgent need for targeted treatment. Annals of Oncology. 2024; 35: S1410. doi:10.1016/j.annonc.2024.10.035.
13. Shin HJ, Kim HH, Huh MO, et al. Correlation between mammographic and sonographic findings and prognostic factors in patients with node-negative invasive breast cancer. Br J Radiol. Jan 2011; 84(997): 19-30. doi:10.1259/bjr/92960562.
14. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol. Aug 2012; 23 Suppl 6:vi23-9. doi:10.1093/annonc/mds191.
15. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging. 2020; 3(1): 12-24. doi:10.1093/jbi/wbaa110 %J Journal of Breast Imaging.
16. Ramírez-Galván, Yazmín & Uribe-Martinez, Minerva & Ponce-Camacho, Marco & Montemayor, Alberto. (2022). Spiculated margin on ultrasound is associated with tumor grade and immunohistochemical profile in breast cancer. Journal of the Mexican Federation of Radiology and Imaging. 1. 10.24875/JMEXFRI.M22000016.
17. Mansour S, Abdullah E, Mohamed EH, Gomaa MMM. Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation. Egyptian Journal of Radiology and Nuclear Medicine. 2023/07/14 2023; 54(1): 122. doi:10.1186/s43055-023-01063-4.
18. Liu G, Li Y, Chen SL, Chen Q. Non-mass enhancement breast lesions: MRI findings and associations with malignancy. Annals of translational medicine. Mar 2022; 10(6): 357. doi:10.21037/atm-22-503.